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Amended proposal for a 
EUROPEAN PARLIAMENT AND COUNCIL DIRECTIVE 
on the legal protection of  biotechnological inventions 
·.,.~ 
(presented by the Co~missio~41.Y..rsu~t to Article 189 a (2) 
of the EC-Treaty) .. 
-EXPLANATORY MEMORANDUM 
GENERAL COMMENTS 
In February 1996, the Commission presented to  European Parliament and the Council :a 
new proposal· for a Directive on the legal protection of  biotechnological inveptions.I 
.  - . 
The  Economic· and  Social  Committee adopted  its  opinion regarding  this  proposal  on 
11  July 1996.2 
European Parliament adopted 66 amendments at its first reading of the proposal during 
its plenary part-session of 14-18July 1997.3  · 
These  aiilendments  reflect  European  Parliament's  concern's  regarding  the  need  (a)  to 
clarify  the  difference  between  discoveries  and  inventions  where  the  patentability  of 
elements of  human origin is concerned and (b) to introduce an ethical. dimension into the 
proposal for a Directive. 
In this  respect, .  this  amended proposal  takes  account of all  of European  Parliament's 
amendments  .. 
There is only one amendment, amendment 76, which the Com~ission  'is unable to. accept. 
·  This proposed the introduction of an Article 8a.  The first paragraph of this amendment , 
required a patent application for an invention consisting of biologiCal material of  animal 
or plant origin to indicate the geographical place of  o~igin of the material in question and 
to provide evidence that the material had. been used in accord(lJlce with the legal access 
and export provisions in force in the place of  origin.  'The second paragraph required that, 
if the biological material was of human origin, the patent application should publish the 
name ·and address of  the person of o~gin or his  or her legal  representative and  also 
provide evidence that the material  had been. used and the patent applied for  with the 
agreement ofthe person of  origin or ofhis orher legal representative.  ·  · 
The first paragraph of  this amendment goes beyond the international commitments which 
the Community and its Member States have entered into in approving and ratifying the 
Coiwention -on  Biological-Diversity of 5 June 1992.4  Moreover, the second paragraph 
does not meet  _the requirements governing the protection of  personal data. 5 
.  .  .  .  .  .  . 
OJ No C 296, 8.10.1996, p.4. 
2  OJ NO C 295, 7  .I  0:1996, p.  11. 
3  Not yet published. 
4  _Council  Decision of 25  October  1993  concerning the  conclusion  of the Convention on  Biological 
Diversity, OJ No L 309, 13.12.1993, p. 1.  · 
5  Directive  95/46/EC  of the  European  Parliament  and  of the  Council  of 24  October  1995  on  the 
protection of individuals with regard to the processing of personal data and on the free movement of 
such data,OJN'o L 281,23.11.1995. ·  · COMMENTS-ON THE RECITALS 
From a general point of  view 
The table below indicates the numbers of  the recitals into which the amendments adopted 
by Parliament have been incorporated. 
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From an individual point of  view 
All the amendmentS to the recitals have been incorporated in full,  except as far -as  the 
folloWing aspects are concerned: . 
-Recital 13 incorporates amendment 11.  Its middle section has been slightly reworded in 
·order to align it on the wording ofArticle 5( 1  ).  - · 
Recital l4a incorporates amendment  13.  The beginning has been slightly reworded in 
order ·to· take better account of  the· need to  finance·. research against rare  or -so-called · 
orphan diseases.  '  ·  ·  ·  · 
Recital 15 incorporates amendment 14.  It has been slightly reworded at the end because 
it is the rights conferred by a patent  and not the patenlitselfwhich are-concerned. 
Recitall6b incorporates amendment 16b.  It has bee~  slightly reworded in order tomake 
it  _clearer  that  it  is  a  DNA  sequence's  hick  of'biologic~l function ·which- makes  it 
unpatentable. 
Redtall6f incorporates amendment 17.  It has been slightly.reworded in order to align it 
on point 2.4. of  Opinion No 8 of the Group of Advisers on the Ethical Implications of 
Biotechnology.  ·  · 
ReCital  l6g summarises amendments  79 and  99  in  the  light of the consequences of 
Article 28(1)(a)ofthe TRIPs Agreement.  · 
Recital 17 incorporates amendment 18, with one slight change: the word "practicability"· 
has been replaced by "application":  · 
Recitall9 incorp,orates amendment 23.  Its wording has been amended to make it legally 
more certain. · -
-Recital19c incorporates the.second part of  amendment 26:  The final clause-has been left 
out because there is nothing to prevent the .patent on a product, e.g. a medicinal product, 
whose commercial exploitation has been authorised from being·annulled if a judge finds 
that one of the conditions for its patentability is not met.  Annulment of the patent does. 
not involve withdrawal of the authorisation to exploit the product co_mmercially.  The 
two procedures are independent C?f each other.  · 
Recital 22 incorporates amendment 80.  The end has been slightly reworded in order to 
avoid  any. incorrect  scientific· interpretation  which. would  be  inconsistent  with  the 
amendment's purpose. 
Recital 23  in~orporates amendment 30~  The_ wording has been amended following the 
deletionofrecital21 by amendment 28 because recital 23 is linked toit:  . 
3 
, I Recital 24a is new.  It refers to the definition of  human reproductive cloning contained in 
Opinion No 9 of  the Group of  Advisers on the Ethical Implications of  Biotechnology.  At 
thC?  same time, it incorporates what was  intended by amendment 55,  paragraph 2(bb). 
This subparagraph better explains why the patentability of  human reproductive cloning is 
, to be ruled  out.  In view of the  need  for  proper drafting, ·  any  redundant  information 
should be avoided in the operative part of the Directive and the explanation should be·· 
incorporated into the recitals. 
R~cital24b  is a summary of  amendments 10 and 33. 
Recital 32 has been given a new wording.  It is aligned on the wording of  Article 31 ( 1  )(i) 
of the TRIPs Agreement in view of the fact that amendment 67 expressly introduces a' 
. reference to the rights and obligations arising out of  that agreement, inter alia, in Article 
1  (2) of  the proposal for a Directive. 
Recital 35 incorporates amendment 38.  The words "because otherwise patenting would . 
be precluded on the grounds of  lack of  novelty of  the invention" have been left out for the 
sake or"clarity and in order to avoid any incorrect technical interpretation. 
Recital  37  summarises  amendments  40,  41,  42,  43,  68  and  77.  Some  of these 
amendments proposed introducing complete quotations of articles from the Convention 
. on Biological Diversity.  It wo1lld appear more appropriate, in view. of  the fact that recital 
40 states that this Directive does not .affect the rights and obligations of Member States 
arising from international agreements, ·and that amendment ·67, cited above, also refers to 
this Convention, to refer globally to the Council Decision of  25 October 1993 concerning 
the conclusion of  the Conven9on on Biological Diversity. 
COMMENTS ON THE INDIVIDUAL ARTICLES 
Article 1(2) incorporates amendment 67. 
Article 2 incorporat~s  ~endment  48, paragraphs 2, 4, 5 and 6. 
Article 3 incorporates amendment 48, paragraphs 1 and 3. 
Amendment 48 has been divided into two articles for the sake of  clarity. 
· Article 4 incorporates amendment 47.  Paragraph 2 of this Article has been amended in 
'  the same way ~  recital 17, amended by amendment 18.  The· word "practicability''  is 
replaced by "application". 
4  . .• 
.  . 
Artic•e 5 incorporates amendments 1  00 and 49. -It corresponds to the former Article 3 . 
Articles4, 5; 6, 7 and 8 hnvc been deleted in  acl~nrdance with antl.·ndnwnts 50. 51. 5). :':1 
and 54' respectively.  This is basically because they ·have been incorporated into Articic 2, 
3 and 4 of  the amended proposal. 
Articl~ 6 incorporates ~endment  5·5.  It corresponds to the former Article 9.  · 
It should be noted that the word "publicatiim" has not been included in paragraph 1. The 
paragraph is-thus consistent with Article 27(2)ofthe TRIPs Agreement. 
. Paragraph 2(bb) of the ari:Iendment  is  not incorporated as  such into Article 6.  See the 
explanation given regarding the new recital 24a.  . 
Article 7 incorporates amendment 78.  As the Commission announced during the plenary 
debate, it considers that, in the context of the request for proposals to  be formulated -on 
-the composition and- terms of  reference of an ethics committee betorc the Directive enters 
into  fo~ce, its Group of Advisers on the Ethical Implications of Biotechnology should be -
made .competent.  In  so  doing,  the  Commission  will  take  accourit  of Parliament's 
Resolution  84-0484/97  of 13 June 1997  on  the  terms  of reference  of the  Group  of 
-Advisers on  the Ethic,al Implications of  Biotechnology. 
,Article 8(1) is unchanged.  It corresponds to the former Article 10. 
Article 8(2) incorporates amendment 57. 
Article  9  is  inspired  by  amendment  58.  It corresponds to ·the  former -Article  11. 
However,  the  reference· in this  amendment  to  Article  2a(1) (i.e.  Article  4(1) of the 
aniended proposal) is technically and_ legally incomprehensible in the light of Article 11 
of the  proposal,  which  introduces  a  derogation  for  farmers,  and  Article  12, ·which 
provides for a system of compulsory cross-licensing where a patent dominates a plant 
variety.  _It  would therefore  not  be.  appropriate  to  include  this  reference  because,  in 
_  practice, this would liinit the scope of  protection conferred by a patent in such a way as to 
-go against current practice under patent law.  .  .  . 
-. 
Article _10 is unchanged;- It corresponds to the former Article 12. 
Article 11 incorporates amendment 59.  It  corresponds to the former Article 13. 
It should be noted that amendment 95, which aimed to amend paragraph 2 of  this Article, 
gives rise to a number of practical difficulties.  The reference to Article 14(1) and (3) of 
Regulation No 2100/94 is incomplete,  Those two paragraphs cannot function without 
paragraph  2  because  it  that  would  render  meaningless  the  idea that  the  derogation 
provided  for  in  Article  11  is  in  accordance  with  the  provisions  on  plant  varieties. 
Moreover; farmers might be confronted With different legal situations.  This would not be 
_  desirable. 
5. 
. ..... ·  ··  ·  · · rpe :final  sentence  of amendment  95  repeats  the· final  sentence  of amendment  59, , · 
.  However. this applies to plants what is specifically laid down for animals, which would 
· not be approp~ate; ·  ·  · 
Article 12(1) and (2) remain unchanged. They correspond to the former Article 14. 
Article 12(3)(b) inco..Porates amendment 60. in accordance with Article 31(1)(i) of the 
TRIPs Agreement. 
Article 12(4) incorporates amendment 61. 
Article 13 is unchanged~ It corresponds to the former Article 15. 
Article 14 is unchanged.  It c'orresponds tothe former Article 16. 
Article 17 of  the initial proposal is deleted in accordance with amendment 62. 
Article 15(1) incorporates amendment 63.  It corresponds to the former Article 18:. 
Article 16 is new.  It  corresponds to amendment (j4. 
Articles 17 and 18 are unchanged.  They correspond to the former Articles 19 and 20 
respectively. 
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Amended proposal for a ·  .  . 
EUROPEAN PARLIAMENT AND COUNCiL DIRECTIVE 
on the legal protection of biotechnological inventions 
·THE EUROPEAN PARLIAMENT AND THE COUNCIL OF THE EUROPEAN 
UNION,  -.. 
Initial proposal  · Amended proposal 
.  . 
··  Having ·regard to the  Treaty  establishing  U11changed · 
· the E\iropean Community, and in particular 
Article 1  OOa thereof,  . 
Having  regard  to  the  proposal ·from  the  Unchanged 
._  Commission,  I 
Having  regard·  to  the · Opinion·  of  the  Unchanged . 
Economic and Social Committee,  2 
Acting  in  accordanc~ with  the  procedure  Unchanged  -
' laid down iri Article 189b of  the Treaty, 3 
( 1)  .  Whereas biotechnology and genetic  ( 1) 
engineering  arc  playing  .  ..  an 
· increaSingly  important  role  in · a 
··broad  range  of industries  and  the 
protection  of  biotechnological 
inventions  will .  certainly  be  -of 
fundamen~  · importance  for  the 
.  / Community's  industrial 
· development; 
(2Y  Whereas  the  investments  required  (~) 
· in  research  and ·  development~ 
particularly for genetic engineering, 
are  especiaJiy  high  and  especiaJiy -
risky  .·  and  .  the  possibqity ·  of 
recouping that investment can only . 
be  guaranteed  effectively  through 
adequate legal proteCtion; · ·  · 
-
{3)  Whereas  without  effective  and  (3) 
hcirmonised  protection.  throughout 
the  Member States  such 
investments  might  wen·  not  be 
made; 
I  .  - .  .  . 
OJ No C 296, 8.1 0.1996, p. 4. 
2  OJNoC295,7.10.1996,p. II. 





· Whereas  effective  and  harmonised 
protection  throughout  the  Member 
·States  is  essential . in  order  to  . 
maintain -and  encourage  investment 
in the field of  biotechnology; Initial proposal 
(  4) ·  Whereas  following  the  European  ··  (  4) 
(5) 
(6) 
· ·  Parliament's  rejection ,of the· joint 
text,  approved  by the  Conciliation 
Committee,  for  a  European 
Parliament  and  Council  Directive 
on  the  legal  ' protection  or 
biotechnological  -inventions,  1  the 
European Parliament  ·  .·  and  the 
. . Council  have determined  that the 
legal protection of biotechnological 
inventions  cannot  be  left  as  it 
. currently stands; . 
. Whereas  differences  exist  in  the  (  5) 
legal protection of biotechnological 
inventions offered by the laws· and 
practices  .of  the  Member States; 
whereas  such  differences  could. 
create  barriers  to  trade  and  to  the 
creation and proper functioning  of 
the internal market; 
Whereas  such  differences  in  legal  (()) 
protection  could  well  become 
.greater as Member States adopt new· 
and.  different  legislation  and 
-administrative  practices,  or  as 
national case-law interpreting  such 
legislation develops differently; 
(7)  Whereas  · the  uncoordinated  (7) 
development  of national  laws  on 
the  legal  protection  of 
biotechnological  inven~ions in  the  · 
Community  CQuld  result  in  the 
.·  creation  of  new  disincentives  to 
·  trade,  to  the  detriment  of  the 
industrial  <fevelopment  of  such 
inventions  and  of  ..  the  smooth 
operation of  the internal market; 
OJ No C 68, 20.3.1995, p. 26. 
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Amended proposal 
-Whereas  following~ the  European 
Parliament's  rejection  of the  joint 
text,  approved  by  the  Conciliatjon 
Committee,  for  a  European 
Parliament and Council Directive on 
the  legal  protection  of 
biotechnological  inventions,  the 
European  . Parliament·  and  the 
Council have  determined  that  the 
· legal  protection of biotechnological 











Initial proposal  Amended ·proposal· 
Whereas  the  legal  protection. of. (8) .  Unchanged 
biotechnological  inventions  does 
not  necessitate  the.  creation  of a 
separate body of law· in place. of  the 
rules·  of  .· national  .·  patent  law; 
. whereas the rules of national paten_t 
law  remain  the  essenthil  basis  for 
the  legal  protection  of 
biotechnological  inventions; 
whereaS,  however,  they  must  be 
adapted  or  added  to  in  certain 
·specific . respects  in  order  to  take  ( 
full  accol}llt  of  technological . 
developments  involvi~g biological 
.  material  which  also  fulfil  the 
: requirements for patentability; . 
(8a)  Whereas  in  .  such  cases  as  the . 
exclusion  from  patentability  of . 
..  ·•  '·· 
.. ::') 
., 
· . plant  and  animal <varieties· and  of 
essentially biological  processes  for 
the  production.·  of  plants  ·and 
animals,  certain  concepts  in 
national  laws ••  based  · upon 
international  patent .  .  and.  plant · 
· variety  conventions  have  created 
uncertainty regarding 'the protection 
of  biotechnological·  and  cert8.in. 
microbiological  inventions; 
whereas harmonisation· is necessary 
to Clarify the said uncertainty; 
\  ' 
/ · Initial propo·sal 
(9)  ._'·.  Whereas harmonisation -of the laws  (9) 
Amended  proposa~­
Deleted.· 
· o_fthe Member Statesis·nec<?ssary to clar~fy 
certain  concepts_  · in  ~tional  laws 
originating · in  certain  international· patent 
and planf  variety  conventions which have 
· leq to s6me· uncertainty as to the possibility 
of pr9tecting. biotechnological  inventions 
concerning  . plant  matter  and  certain 
· microbiological ·inventions,  concepts  such . 
as the exclusion from patentability of  plant -
and  animal  .varieties  and  -of  essentially 
biological· processes for the production of 
•'<"  o"  "·,'  <  L  -!  1 
plants and animals;  · . .  _  . 
.·  .. 
, ..  · 
(9a)  Having  regard  to  the  potentiar of. 
the  development  of biotechnology  ~ 
for  the.  environment  . and  tn 
particular  the  utiJity  of.  this 
·technology for  the  development of 
methods  of cultivation  which  are· 
less polluting and more economical 
· in their lise  of  ·land;  whereas  the 
patent  system  should  be  used  to 
encourage  research  into,  and  the 
application of, such-procedures; 
.  .  .  ·- .  '  "· 
-10 
''  i' 
,.  . 
i 
.. / 
Initial proposal.  Amended proposal 
(9b)  Having regard to the importance of 
. · the  developm~nt of biotechnology 
. to developing CO\¥}tries, bot4 in the 
.. field of  health and comb~ting major . 
- epidemics  and  endemic  diseases 
.  . and in that of combating hunger in . 
the  · world;  wher:~as  the · patent 
system  should' iikewise be  used. to 
encourage  research  in  these  fields; 
whereas  international  procedures 
for  ·the.  dissemination  of  .  such 
technology in the Third World and 
to  the . benefit  of the  population 
groups·  .  concerned  should  be · 
promoted;· 
(9c)  Whereas  the.  TRIPs  Agreement 
11 
.  signed by the European Cpmmunity 
and the Member States has entered 
into .  force  and provides that patent 
protection  shall  be  guaranteed  for 
products and processes in all  areas 
of  technology; Initial proposal  Amended proposal 
(1 0)  Whereas  the  Community's  legal  (1 0)  .  Unchanged 
framework  for  the  protection  of 
biotechnological inventions can be 
limited  to  laying  down  certain 
principles  as  they  apply  to  the 
patentability of biological  material 
as  such  - such  principles  being 
intended, in particular, to determine 
the  difference  between  inventions 
and discoveries with regard  to  the 
patentability ·of certain elements of 
human origin - and can be· further 
limited to defimng the scope of the 
protection accorded by a patent on a 
. bioteChnological  invent~ori,  to  the 
right to use a deposit mechanism in 
addition to written descriptions, to a 
reversal of the burden of proof and 
to  the  option  of  obtaining 
non-exclusive  compulsory  licences 
in  . respect  of  interdependence · 
between  plant  varieties  and 
inventions; 
(11)  Whereas a patent for invention does  (11). 
not  authorise  the  holder  to 
implement  that  invention,  but 
merely entitles him to prohibit third 
parties  from  exploiting  it  for 
industrial  and  commercial· 
· purposes;  whereas,  consequently, 
substantive patent law cannot serve 
to. call  into  question  national  and 
Community law on the  monitoring 
of  research  and  of  the  use  or 
. comn1ercialisation  of  its  results, 
notably  from  the point of view of 
. the  requirements  of public  health, 
safecy,  environmental  protection, 
animal welfare, the preservation of 
genetic  diversity  and  compliance 
'with certain ethical standards; 
Whereas a patent for invention does 
not  authorise  the  holder  to 
implement  that  invention,  but 
merely entitles him to prohibit third 
parties  from  exploiting  it·  for 
industrial  and  commercial 
purposes;  whereas,  consequently, 
substantive patent law cannot serve 
to  replace  or.  render  superfluous 
nationala... European  or· international 
law which may  impose restrictions 
oi. prohibitions .  or which  concerns 
the  monitoring of research  and  of 
the use or commercialisation of its 
results,  notably from  the  point  of 
view of the requirements of public 
"health·,  safety,  animal  welfare,  the 
preservation.  of  genetic  diversity 
and compliance with certain ethical 
standards; 
..  r 
'. .. 
Initial proposal. 
..  (12)  Whereas  ·no  pro~ibitiori  or  (12) 
exclusion  ,exists  in  national  or 
European  patent  law  · (Munich 
·.Convention).  , which  precludes 
a pr.zon  the ·  patentability  of · 
biological matter; 
(13)  Wh~reas it should be  SP,ecified that  (13} 
knowledge  relating . to  the  human 
(14) 
body  and  to  its  elements  in  their 
natural 'state falls  within the  realm 
of scientific disco~ery and may. riot, 
'therefore, _be  regarded as patentable' 
inventions; whereas it follows from 
this  that  substantive  patent  law  is 
not capable of prejudicing the basic 
ethical  principle  excluding  all 
ownership o~  human beings; · 
WhereaS  significan~ progress in the · 
treatment. of diseases  has  already 
been  made  thanks·  to  mediCinal 
products  derived  or  otherwise 
produced  from  dements  isolated 
from  the .  human  body,  and 
· medicinal products resulting from  ~ 
technical ·  process.  aimed  at 
obtaining  elements  similar ·  _in 
. structure to those existing naturally . 
in  the  huinan ,·b9dy  and  _whereas, 
consequently,  . the  patent  system · 
should  promote  research  aimed  at 





Unchanged  . 
Whereas. patent  law  must  ~espect . 
.  the-·  fund~unental  prindples 
safeguarding  .·  the  dignity  and 
integrity of  the person; whereas it is 
important to assert the principle that 
the human body, at any stage in its 
formation  or  development, 
·including germ cells, and the simple . 
discOvery of one of its elements or 
one  of its  products,  including  the 
sequence  or partial  sequence  of a 
hum~  ·gene,  cannot .  be  patented: 
whereas these principles· are in line 
with  the . criteria  of  patentability 
proper  to  patent  law, . whereby  a 
mere discovery cannot be patented;. 
Whereas significant progress in the 
treatment  ·of. diseases  has ·already 
·been  made  thanks  ·to  medicinal 
products  derived  and/or  otherWise. 
produced  from  elements  isolated 
from  the  human  . body,  and 
medicinal  products  resulting  froin 
technical  . · processes  aimed  at 
obtaining  elements  similar ·  in 
structure to those existing naturally 
i:Q  the.·human- body  and  whereas, 
consequently,  the . patent  ·system 
~ · should  promote  research ·aimed  at 
obtaining  and  isolating·  such 
elements  valuable·  to  medicinal 
production; (15) 
Initial proposal  - Amended proposal _ 
( 14a)  Whereas,  since  the  patent-system 
provides  insufficient  inc_entiye_ for 
financing  research  into  and 
production  of  ·biotechnological _ 
medicines  which  are  needed -to 
combat rare or 'orphan' diseases, the 
Community and the Me~ber  States 
-have  a  duty to respond adequately 
to this problem; 
(14b)  Having regard to Opinion No 8 by 
the  Group  of  Advisers  on  the 
Ethical  Implications  ·.  of 
Biotechnology  to  the  European 
Commission; 
Whereas,  therefore,  it  should · be  (15) 
made  clear  that .  an  invention 
capable  of _  industrial  application 
.. Whereas,  therefore,  it  should  be 
made clear that an  invention based 
on  an  element  isolated  from  the 
human body or otherwise produced 
by  means  of a  technical  proc~ss, 
which  is  capable  of  industrial 
application,  is  not  excluded  from 
patentability,  even  where .  the 
structure of  that element is identical 
to that of a  natural  ele~ent, while 
the rights conferred by the patent do 
not extend to  the  human 'body and 
its  elements  in  their  natural 
environment; 
and  based on  an  element  isolated· 
from the human body or otherwise 
produced. by means  of a  technical 
process  is  patentable,  even . where 
the  structure  of  that  element  is 
identical  to  that . of  a  natural 
element,  since  no  patent  may  be 
interpreted as  covering an  element 
!lf the  human  bOdy· in  its  natural 
environm~nt . forming  the  basic 
·subj~t  ofthe  iriventi~n. 
14 (16). 
Initial propo.sal. ·  -.  Amended pro~osal 
Whereas  such  an  element  isolated  (16) 
from the' hl,lillan  body or ·otherwise .• 
produced  may  not  be  .. regarded  as 
unpatentable in the same way as an . 
Whereas  such  an  element  isolated 
from  the  human body· or otherWise 
produced  is  not·  excluded  from 
patentability  as  it is,  for example, . 
the· result  of the  technical  process· 
used to  identify, pirrify and classify 
.  element .of the human body  in  its 
. natural state, that is to say' may not 
. be equated with a discovery,' since 
the element· isolated is the  re~:i.dt of 
the  tec}mical  processes  1:1sed  to 
identify,  purify  and  classify  it and 
to .reproduce  it outside  the  human 
body,  techniques  which  human . 
beings· alone are capable of putting 
into  practice  and  which  Nature  is 
incapable . of ·  accomplishing  . by 
itself; 
.  f' 
.-
· it· and  to· reproduce .  it  outside  the 
human·  ...  body,  techniques  which 
humari  beings alone are capable of 
.  putting  into  practice . and  which 
Nature  is  incapable  . of 
accomplishing by itself; 
(16a)  Whereas  the  discussion  on  the 
patentability of sequences or partial 
sequences of genes is controversial; 
whereas,  . according  to  this 
Directive,  the  granting  of a -patent 
for  inventions which concern  such 
sequences  or  partial  sequences 
.require  the  saine,  criteria  to  b~ 
applied  as . in  all..  other  areas  of 
techl1ology; 
(16b)  Whereas a mere sequence of DNA 
segments _  without  indication  of a 
biological function does not contain 
a technical teaching and is therefore 
not a patentable invention; . 
(16c)  Whereas  a  sequence  or  partial 
sequence  can  be  the  subject  of a. 
patentable .  invention  when. all  the 
necessary  conditions  for  a  patent . 
are  satisfied:  novelty,  level  ~f 
. invention and_industrial application; 
15 Initial proposal 
!  .. 
Amended proposal 
(16d)  Whereas  for  ·the  criterion  of 
industrial  application  to  be 
coniplied with. the genetic sequence 
or partial sequence and thus also the 
protein for which a DNA sequence 
codes must be determined; whereas 
for sequences which overlap,  each 
sequence will  be considered as. an 
· independent sequence in patent Jaw 
terms;· 
(16e)  Whereas 
disclosure 
the  requirements  for 
of  the  industrial 
application  of  the  seque.nces  or 
partial sequences do not differ from 
those ·in other areas of technology; 
whereas  at  least  an  industrial 
application  must  be  actually 
disclosed in the patent application; 
(16f)  Whereas  the  free  and  informed 
consent of the  person from  whose 
body material. is taken is required in . 
order for an application to be made 
for a patent in respect of the use of 
that material;· 
(16g)  Whereas  this  Directive  in  no  way 
affects  the  basi~ of current  patent 
law,  according  to  which  a  patent 
may  be  granted_  for  any  new 
application of  a patented product; 
16 Initial proposal 
(17)  Whereas,  in  order  to  determine.  the 
extent  to  which  plant  and  ·animal 
· varieties  are  to  be·  excluded  from 
patentability,  1t  should  be  specified 
that  the · exclusion  concerns  those 
varieties  . as  such  and  that, 
consequently, it does not prejudice the 
patentability .·of  plants  or  . animals 
obtained  by·  means  of a  process  at 
least one stage of  which is essentially 
microbiological,' irrespective.  of  the 
basic biological material to  w~ich  that 
process ·.isapplied; 
. -·  ~' 
( 17)-
Amended proposal . 
Whereas  t11is  Directive  . shall  he. 
without. prejudice  to  the  exclusion 
of plant and· anim~l varieti~s from 
. patentability;  whereas on the .othe·r 
· hand · inventions · which  concern 
plants  or. ariimals  are  in  general 
patentable  .  provided  that  the 
~ application  of the .  invention- is  not 
technically , confined  to .  · a  single 
plant or animal variety;  . 
(17a)  WJ:iereas  the concept 'plant variety' 
. is·  defined  by  the  law  protecting·. 
new varieties, .  pursuant .  to  which a 
variety ·is  defined  by  its  whole 
genome  and  therefore  possesses ·. 
_individuality;  whereas  it  is  clearly 
distinguishable from other varieties; 
(17b)  whereas  a  plant totality .which  is • 
charaCterised .  by  a.  particular  gene 
.(and  not its  whole  genome)  is not 
covered  by  the · protection  of new 
varieties  and  is  therefor~  ·.  not 
excluded fro  in patentability· even if' 
it  comprises plant varieties; 
.\ 
(  . 
17 .Initial proposal  ·Amended proposal 
(17c)  Whereas,  however, if an invention 
consists  only  in  genetically 
modifying a particular plant variety, 
it  ' shall  ' be  '  excluded  from 
patentabil~ty  even  if  the -genetic . 
modification  is ·the  result  not  of 
breeding  . but  of ·  a  genetic 
engineering procedure; 
(18) 'Whereas,  for  .  the  purposes  of  (18) 
determining  whether.  or . not  it .  is 
.  Whereas  a  procedure  for  the 
breeding  of plants  and  aniinals .  is 
essentially  biological if it is  based 
on  crossing  whole  genomes  (with 
subsequent  .~election  and  perhaps 
further crossingofwhole genomes);. 
. possible ·  to  patent  essentially 
biological  processes.  for  obtaining 
plants or animals, ·human intervention 
and 'the effectS  ~f  that intervention on 
the.resultobtained·lnust  b~ taken into 
account; · 
(19)  Whereas  national  patent laws  for  (19). 
inventions contain provisions.as to the · 
criteria . for  alloWing  or  exchidi~g 
paten~bility, including· provisions  to 
the  effect ·that :a  patent  may  not· be 
granted· · in  respect  of  inventions 
' whose  puplication  or  exploitation 
would be coni:r~  to public· policy or 
,.  .  .mm~ality; 
Whereas  this  Directive · shall . be 
without  prejudice ·to  concepts  of 
invention  .  and  discovery,  as  . 
developed. by  riation~l, European or· . 
international patent laws;  · 
·  ( 19a)  Whereas  this  Directive  shall  be 
without prejudice to  the provisions 
of  national  paterit  law  whereby 
surgical  ·or  therapeutic  treatment 
procedures applicable to the human 
body  or the bodies of animals. and 
diagnostic  procedures  which.  are 
carried .out  on the  human body or 
18 





Initial proposal  Amended proposal 
(19b)  -Whereas·  the_  TRIPs  Agreement 
- provides  for  t~e  possibility  that 
members - of  the  World  Trade 
Organisation  may  exclude  from 
patentability  -inventions  -_whose 
commercial  exploitation  within 
their territory must be prevented in 
order  to  protect  public -policy  or 
mor~~ity,  including  to  protect 
human  or  animal  life  or health,  to 
preserVe plants or to prevent serious 
-harm  to  the- environment, provided 
that  such  -an  --~·exclusion  is  not 
undertaken  solely  because 
exploitation  is  prohibited  by  their 
legislation; 
(19c)  Whereas  other · prohibitions  O'n 
exploitation under national law are  -
not  suffiCient - · to  exclude 
patentability;  whereas  such  an 
exclusion·  presupposes  that  the 
commercial  exploitation  of  the 
invention  is - prohibited ·  m  the 
Member State in question; 
-, (20)  Whereas· such  a  reference  to  public  (20) 
policy  and  morality  should  be 
included-in the operative part  ~f this 
Directive in order. to bring out the~ fact 
Whereas  the  principle - whereby 
inventions  must  be  excluded  from  --
patentability  where  their 
commercial  exploitation.  offends 
against  public  policy  or  morality  that  ·  some  applications  of 
· biotechnological inventions, by  ~irtue 
of  some  of  thei_r  consequences  or 
e£rects,  'are  capable  of -offending-
against them; 
19  -
-must  also  be _ stressed  m  this 
Directive; 
/ Initial proposal  Amended proposal 
(21)  Whereas  it  must  be  determined  (21)  Deleted 
whether applications offend against 
(22) 
public policy and morality in each 
specific  case,  by  means  of  an 
appraisal  of. the  values  involved, 
whereby  the .  benefit to be. derived 
· from  the  invention, · on  the  one 
hand,  is  weighed  and  evaluated 
against  any  risks  associated 
therewith, and any objections based 
on fundamental  principles  of law, 
on the other hand; 
Whereas the operative  part of this  (22) 
Directive  should  also  include  an 
illustrative  - list  of  inventions 
excluded from patentability so as to 
provide  national  cow:ts  and patent 
offices  with  a  general  guide  to 
interpreting the reference. to public 
policy or morality; 
20 
Whereas  the  operative .part of this 
Directive. should  also  include  an 
illustrative  list  of·  inventions 
excluded from patentability so as to • 
provide  national courts  and  patent 
offices  with  a  general  guide  to 
interpreting the reference  to public 
policy  and  morality;  whereas· this 
. list  cannot .  presume  to  be 
exhaustive;  whereas  pr~cesses the 
use of which offend against human 
dignity,  such  as  processes  to 
produce chimeras from a mixture of 
huinan  and  animal  genomes,  are 
also excluded from patentability; 
'  + (23). 
Initial proposal 
Whereas such moral considerations  (23) 
must  be .  given  greater · weight  in 
appraising  the  patentability  of 
biotechnological  inventions,  both 
~m account of  the subject-matter of' 
this  branch_  of  science,  namely· 
living  matter,  and  because  of the 
often  far-reaching  implications  of 
the  inventions  to·  be  examined~ 
whereas  these  ·considerations  do 
not, however, change the  nature of 
patent law as a primarily technical 
body of law and ·are  no  substitute 
for  the  other  legal  checks  which 
biotechnological  - inventions  are 
required to  _undergo  from  the  start 
of  their  development ' or  at . the 
marketing  stage,  particularly  ~ith 
r~gatd  to safety;  .  · 
(24)  Whereas, in view of the importance  (24) 
and the controversial nature of the 
unprecedented  questions  raised  by 
germ ·  · line  gene  therapy,  it  is 
important to  exclude-unequivocally 
from  patentability  methods · of 




Whereas  monility.  represents  the 
ethical or moral principles generally 
observed  in  a  Member State.  or 
accepted  by  the  scientific  ·or 
professional  circles  concerned; 
whereas it is  particularly important 
that these principles be respected in 
the field  of biotechnology  in view 
of the potential' scope of inventions 
in  this  field  and  their  inherent 
relationship  to  living  matter; 
whereas  such  ethical  or  moral 
principles  supplement the  standard 
legal  checks  of  patent  _  law 
regardless of the  technical  field  of 
the invention; 
Whereas  m.  the  European· Union 
· there  IS  a  consensus  that  · 
interventions  in ·  the  human  germ_ 
line  and  the  cloriing  of  human 
beings offends against public policy 
and morality; whereas it is· t.p.erefore 
important to exclude unequivocally 
from  patentability  methods  for 
intervention  in  the  germ  line  ·of 
human  beings  and  processes  for 
cloning htunah ·beings; -Initial proposal  Amended proposal 
(24a)  · Whereas  in  the  European  Union 
there  is  a  consensus  that 
interventions  in  the  human  germ 
nne  and  .  the  cloning  of  human 
beings offends against public policy 
and morality; whereas it is therefore 
22 
·-important to  exclude uneqUivocally 
from  patentability  methods  for · 
intervention  in  the  germ  line  of 
human  beings  and  processes  for 
. cloning human beings; ·' 
Initial pro.,osal  Amend~d  p~oposal 
(24b) · Whereas  this Directive  does  not 
affect ·  the.  application  of  the 
Convention on  Human  Rights  and 
Fundamental.  Freedoms  of  4 
. November  1950,:  the.  Convention 
for  the  protection of human rights 
arid the dignity of  the human person 
with  respect  ~o.  applications  of 
biology ·and  medicine:  Convention 
on human rights and biomedicine of 
19.  Novem~er 1996, . or  any  ~ther 
international instrument concerning· 
the protection; of human  fights  on 
which  the  Member  States  have 
cooperated  cir  to . which they  have . 
acceded; 
(25)  Whereas  processes  for  modifying  (25) 
the · genetic  identity  of  animals. 
which  are  likely  to -cause  them 
Whereas  processes  for  ·modifying 
. the  genetic  identity  of  animals . 
which  are  likely  ·to  cause  them 
suffering  without  ahy  substantiat 
medical (diagnostic or therapeutic) 
benefit to man or animal, and also 
· ~.suffering  or  · physical  handicaps 
without  any  substantial  benefit  to 
man  or animal,  and  also  animals . 
resulting from such processes must 
· be  . excluded  from  patentability 
· insofar as the suffering or physical 
handicaps  inflicted  on  the  animals 
concerned are o~t  ·of proportion to 
the objective pursued;  · 
"'  '.  . 
animals  · resulting  from  such 
processes, . must  be  excluded  from 
patentability; Initial proposal  Amended proposal 
(26)  whereas, in view of  the fact that the  (26)  Unchanged 
function ofa patent is to reward the 
.  inventor for  his creative efforts by 
granting  an  exclusive  . but 
time-bound  right,  and  thereby 
encourage  inventive  activities,. the 
holder  of  the  patent  should  be· 
entitled  to  prohibit  the  use  of 
·patented  seW-reproducible  material 
in  situations  analogous  to  those 
where  it  would  be  permitted  to 
prohibit  such  use . of · patented, 
non-self-reproducible  . products, 
namely in respect of  the production 
of  the patented product itself; 
(27)  Whereas it is necessary to provide  (27)  Unchanged 
for a first derogation frop1 the fights 
of  the holder of  the patent when the 
propagating  material  incorporating 
the protected invention is sold to a 
farmer for farming purposes by the 
holder .  of the  patent  or  with  his 
co:t15ent;  whereas  that  initial 
derogation  must  .authorise·'  the 
farmer  to  ·use  the  product  of his 
luirvest for further multiplication or 
propagation  on  his · own.  farm; 
whereas  the  extent  and  the 
conditions of ~t  derogation  must 
be· limited  in  accordance  with  the 
extent  and  conditions  set 
Council  Regulation  · 
No 2100/94;1 
out  in 
(EC) 
(28)  Whereas  only  the  fee  envisage.d  (28)  Unchanged 
under  Community  plant  variety 
rights  as  a  condition  for  applying 
the  derogation  from  Community 
plant variety rights can be required. 





Initial proposal  Amended proposal 
(29)  Whereas, however, the holder of  the  (29)  Unchanged  . 
patent may defend his rights against 
a farmer abusing the derogation or 
against  the  breeder·  ·who  .·  has 
develope<;l  the  ·plant .  variety 
incorporating  the  protected 
invention if  the .hitter fails to adhere 
to his commitments; 
(30)  Whereas a second derogation from  (30) 
. the rights of  the holder of  the patent 
must authorise the farmer to use the 
protected  livestock  for  breeding 
purposes 'on his own farm,  in order 
to replenish their numbers; 
Whereas  a second derogation from 
. the rights of  the holder of  tlie patent· 
must authorise the farmer to use the 
protected iivestock · for ·agricultural 
purposes;· 
(31)  ·.  Whereas  the  extent  and ·  the  (31)  · Unchanged 
(32) 
conditions  of  .  that  second · 
derogation  may  be  determined  by 
national  laws,  regulations  and 
practices,  since  there  is  ·  no 
Community  legislation  on  animal 
variety rights; 
Whe.reas, in the· field of  exploitation 
of  new  plant  characteristics 
resulting from  genetic engineering, . 
guaranteed  access  must,  on 
payme~t of a  fee,' be  granted· in  a 
Member State  in  the  form  of a 
compulsory  licence  where;  in 
relation  to · the  genus  or  species · 
concerned, public interest  d~mands 
the exploitation of the plant v.ariety 
for  which the. licence  is  requested 
and  'the  plant  variety  represe_nts 
significant technical progr~ss; 
(32) 
25 
Whereas, in the_field of  exploitation 
of  . new  plant  characteristics 
resulting· from  genetic' engineering, 
guaranteed  access  must,  on 
payment of a fee, be granted in the 
form  .  of  a  compulsory  licence 
where,  in  relation to  the  genus  or 
species concerned; the plant var~ety 
represents .  significant  technical 
progress . of considerable  economic 
interest  compared to  the inventimi 
. claimed in the patent; (33) 
.  I 
Initial proposal  Amended proposal 
Whereas, in the field of the use of  (33) 
new  plant  characteristics  resulting 
Whereas, in the .  field  of the use of 
. new. plant  characteristics  resulting 
from new plant varieties in genetic . 
engineering,  guaranteed  access 
against a fee must be granted in-the 
form of  a compulsory licence where 
the invention represents significant 
technical  progress  of considerable 
economic interest; 
from  new plant varieties in genetic 
engineering,  guaranteed  access 
against a fee must be granted in the 
form of  a compulsory licence. where. 
public  interest  demands  the 
exploitation  of the · invention  for 
which the  licence  is  requested and 
where  the  invention  represents 
significant technical progress, . 
(34)  Whereas  the  TRIPs  Agreement 
·contains detailed provisions on the 
burden of proof which are binding 
on  all  Member  States; · whereas, 
therefore,  a  provision  in  this 
Directive is not necessary; 
(35)  Whereas  the  ·Commission  will 
investigate whether,  in the field of 
basi~ genetic engineering research, 
free  and  unimpeded  scientific 
exchanges  are  hampered  because· 
publications containing  ~nformation 
which  might  be  patentable  are 
delayed  or  not  undertaken, .. as  a 
result of which patentability would 
be excluded because of the lack or' 
novelty on the part of the inventor; 
whereas the Commission will carry 
out  a  comparison  with  the .  patent 
law of the United States and Japan 
in  this· respect  and  report  to  the 
European  Parliament  and ·  the 
Council  two  years  after  the  entry 
irito force of  this Directive; 
26 .. 
Initial proposal_  Amended proposal 
OJ No L 309, 13.12.1993, p.  1. 
.  (36)  Whereas  the  Commission  will 
report  [annually]  to  the  European 
Parliament  on  the  development  of . ' 
patent  law  in  the  fieid  of 
biotechnology  ·and  ·.  genetic 
engineering; 
· (37)  ~ereas the rights. and obligations 
of the Member States derived from 
international·  agreements, 
particularly_  further  to  the .  Council 
Decision of 25 October 1993 on the 
27  ' 
· conclusion  of the  Convention  on 
Biological  Diversity,1  and  Articles 
3, S(j),  16(2), second sentence, and 
16(5)  of  the.  Convention  on 
Biological  . Diversity  of 
5 June 1992, are not affected by this 
. Directivl!; . Initial proposal  Amended proposal 
(38)  Whereas  the  Third  Conference  of 
the  Parties·  of  the  Biodiversity 
Convention  ,  which  took place  in 
November 1996, noted in Decision 
III/17 that 'further work is required 
to  help ·  develop  a  common 
appreciation  of  the  relationship 
between intellectual property rights 
and  the  relevant  provisions  of the 
28 
TRIPs  ·  Agreement  and  .  the 
Convention  on  Biological 
Diversity,  in  particular  on  issues · 
relating  to  technology  transfer and 
conservation and sustainable use of 
biological diversity and the fair and 
equitable sharing of benefits arising 
out of the use of genetic resources, 
including  the  protection  ·of 
knowledge,  innovations  and· 
·practices  of indigenous  and  local 
communities embodying traditional 
. lifestyles  relevant  for  the 
conservation and sustainable use of 
biological diversity'; ,, 
•  '; 
/ 
• 
ln~tial proposal  Amended proposal 
HAVE ADOPTED THIS DIRECTIVE:  HAVE ADOPTED THIS DIRECTIVE: 
:  ·,. 
,CHAPTER I  CHAPTER I 
Patentability  ··Patentability 
·, 
Article I  Article I 
1.  Member States  shall  protect  1.  Unchanged 
biotechnological inventions under national 
patent  law..- Member States  shall,  if 
necessary,  adjust their national patent law 
to  take  accou.'lt  of the  provisions  of this 
Directive.· 
2. This Directive shall be without prejudice 
to·  national  and  Community  laws  on  the· 
monitoring of  research  and  of the  use  or 
commercialisation of  its results  .. ·  ' 
2. This Directive shall be without prejudice 
to  the.  obligations  of the  Member States· · 
pursuant to  international· agreements, ·and 
in  particular the Convention on Biological 
·  Diyersity and the TRIPs Agree·ment.  · 
·-··  .· 
·Article 2  Article 2 
For the purposes of  this Directive,  1. For the purposes of  this Directive, 
'  ....  i 
1. 
2. 
Biological . material  means  any  (a) 
; material.  containing  genetic 
·information  · and  capable.  of 
self-reproduction·  or  of  · being 
reproduced in a biological system~ . 
Microbiological process means any  (b) 
process  involving  or  performed 
.  upon or resulting in microbiological 
material;  a  process  consisting of a · 
succession of steps shaH be  treated 
as  a  microbiological ·process if at 
least  one:  essential  step  of  the 
.  process_is microbi()logical~ . 
29 
Biological  material  means  any  .. 
material  containing  . genetic 
information  .and  ·capable  of 
reproducing  itself  ot  being 
reproduced in a biological system; 
Microbiological process means any 
process  involving  or  perforlned 
,.  upon or resulting iJ1 microbiological 
·material.  · 3. 
Initial propo~al  Amended proposal 
Essentially  biological  process for  2. A procedure for the breeding of  plants or 
the production of  plants or animals  animal!i  shall  be  qefined  as  essentially 
means any  process which, taken as  biological  if it  1s  based· on  crossing  and 
a  whole,  exists in  nature  or is  not  selection. 
more than_ a natural  plant-breeding 
or animal-breeding process. 
3. The concept plant variety is defined by 
Article 5 ofRegulation (EC) No 2100/94. 
· Article 3 
1. For  the . purposes  of  this  Directive, 
inventions··  which  are  no':'el,  imply 
inventive  activity  and  are  capable  of 
industrial  application  shall  be  patentable 
even if  they concern a product consisting :of 
or·  containing  biological  material  or  a 
procedure  by  means  of which  biological 
material_ is produced, processed or used. 
2. Biological  material  which  is  isolated 
from its natural environment or processed· 
by rrieans of  a technical process may be the ·  · 
subject of an invention even if it already 
occurred in nature. 
Article 4 
1. The following shall not be patentable: 
(a).  plant and animal varieties, 
(b)  essentially biological procedures for 
the breeding of  plants and animals. 
2. Inventions  which  concern  plants  or 
animals may be patented if the application 
of  the invention is not technically confined 
to a particular plant or anjmal variety. 
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I'.· Initial proposal· 
,,,;.  ·. 
.  ;:  ,,· 
_  :.:  , 
:  ;  .  .  '  ' 
.. 
.  .•· 
Ame~ded  proposal 
3. Paragraph  1  (b)  . shall  be ·  without 
prejudice to the' patentability of inventions 
' which .concern a _microbiological  or -other 
technical procedure or a  product obtained 
by means· of  such .a procedure. 
_/  __ 
''  ' 




l.The human  body  arid  its  elements  in  . ·1. The.human body, at the various stages of 
their rtatural  state  shall  not  bee considered  its·  formation  and  development, · and  the 
patentable inventions;  sim,ple  discovery  of o'ne  of its  elements 
inCluding the ·sequence or partial sequence 
of  a  gene,  cannot  constitute  patentable 
inventions. 
r 
2. No~thstanding  paragraph 1, the subject  2. An  element·  isolated  from  the .human 
, of.  an ' invention  capable , of , industrial  body:  oi:' otherwise produced by means of a 
application. which  relates . to  an  element . technical proces~ including the sequence or. 
isolated' from the human body or otherWise  partial sequence of a gene may constitute a 
prodttced by means of a technical process  patentable invention,  even. if  the  structure 
shall be. patentaple, even if the. structure ·of  of that  element  1s- identical  to  that  of a· 
' that element is identical to that of a natural  natural  element' 
element: 
3. The function of a sequence or  ~· partial 
sequence of  a gene must be disclosed in .the 
· patent application. 
· Artic(e 4 
1. The subject of an invention shall not be . 
considered  unpatentable  merely ··  on  the 
grounds' that ,it is composed of,, uses, or is 
applied to biological material. 
2: Biological matc~ri~; including plants ami 
animals, as well as elements of plants and 
aniqtals obtained by means of  a process not 
essentially  biological,  except  plant  and 
animai · · varieties  ·as  such,  · shall  .  be 
. p~tentable;  .· · 
Deleted. 
Arficle 5  Deleted 
Microbiological  processes  and  products 
·  obtafr1ed by means of  such processes ·shall  -" 
be. patentab!e.  · 
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Article 6 
Essentially  biological  processes .. for  the 
production of  plants or animals shall not. be . 
patentable. 
·Article 7 
Uses  of  plant  or  animal  varieties  and 
processes for  their  productign,  other than 
essentially>  biological  processes.  for  the 
production of plants  or animals,  shall  be . 
patentable: 
Article 8 
The  subject of an  invention concerning  a 
biological material shall not b~ considered 
a discovery or lacking in novelty merely on 
the .grounds· tti:at it already formed· part 'of 







1. Inventions  .  ·  shall  be  considered  l. Inventions  shall  be  considered 
.  unpatentable where  exploitation ·would be  unpatentable  where  their  commercial 
contrary  to  public  policy  or  morality;  exploitation·  ~<mid be  contrary  to  public 
however, exploitation shall nor be deemed  policy  or· morality;  however; exploitation 
contrary merely because it is· prohibited _by  · shall  not .  be  deemed  ·to  be  so · contrary 
law or regulation.  ·  - merely because  it is prohibited by  law or 
regulation. 
· 2. On  the  basis  of  paragraph  1,  the  2. On  the  basis  . of  paragraph  1,  the 
follo~ing shall be considered unpatentable:  following shall be considered unpatentable: 
(a)  methods  of  human  treatment  (a) 
involving germ line gene~  therapy; 
33 
procedures for  human reproductive.· 
cloning; Initial proposal  Amended proposal · 
(b)  processes. for  modifying  the. genetic  (n) 
identity of  animals which arc likely to 
cause  them  suffering  or · physical 
processes  for  modifying  the  germ 
line  genetic  identity  of  human 
beings; 
· handicaps  without  any  substantial 
·benefit  to  man  or  animal,  and  also 
animals  r~sulting  from  such 
processes,  whenever the  suffering or 
physical  handicaps  inflicted  on  the 
animals  concerned  are 
disproportionate  to  the  objective 
pursued. 
(c)  methods  in  which  human  embryos 
are used; 
(d)  processes for modifying the genetic-
identity of  animals which are likely 
to cause them suffering without any' 
substantial medical benefit to man 
or animal and also animals resulting 
from such processes; 
Article 7 
The Commission's  Group of Advisers on 
the  Ethical  Implications of Biotechnology 




Initial proposal  Amended proposal 
_  CHAPTE,R II  CHAPTER  II 
Scope of protedion  Scope of protedion 
Article 10  Article 8 
1. _The protection conferred by a patent on a  1. Unchanged 
biological  material · po~sessi9-g  specific 
characteristics ·as a result of the invention 
shall  extend  to . any  biological  material 
_  derived  from  that  · biological  material 
thro~gh multiplication or propagation in an· 
identical or divergent form  and possessing· 
those same chanicteristics. 
2. The protection conferred hy a patent on a  2. The protection conferred by a patenton a 
process that enables a biological material to  process that enables a biological material to 
-be  · produced  possessing  specific  be  produced ·  possessing  specific 
_characteristics as a result of the-invention  characteristics as  a result of the  invention 
shall  e~tend to biological material-' directly  shall extend to biological material ·directly 
obtained  using  that  process  and  to  any  obtained  through  that process  and  to  any 
other biological material derived from  the  -other biological material  derived from the 
biological  material  directly  _ obtained·  biological  material  directly  obtained 
through multiplication or propagation in an  -through multiplication or propagation in an -
identical or divergent form and possessing  · identical· or  dive~gent form and .possessing 
those same characteristics. That protection  those same characteristics.  · 
shall  not  affect  the  exclusion  from 
patentability-of plant and  animal  v~eties 
as ~uch, pursuant to ArtiCle 4(2). 
Article I 1  Article 9 
The_ protection conferred -by  a patent on a  The protection conferred by  a patent on a 
product c~ntaining or consisting of genetic·  product cont~ining or consisting of genetic _ 
information  shall  extend  to  all  materiai,  information  shall  extend  to  all  material, 
- .  -
s~ve_as provided_ in Arlicle 3(1), in which  ·save as provided in Article 5(1), in which 
the product is  inco~rated and  in which  the  product  is  incorporated  and in  which 
the_ genetic  infonnation  is  contained  and  the  genetic  information .  is  contained  and 
expressed.  expressed. -
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Article 12 
_  The  protection referred ·  to  in  Articles  10 
and  11  shall  not  e~tend  to  biological 
material  obtained· from  the  multiplication 
. or  propagation  of  biological  material 
marketed in the territory of  a Member State 
by  the  holder  of the  patent  or  with  his 
consent,  if  the  . multiplication  or 
propagation  necessarily  resul~s  from  the 
application  for  which  the  biological 
material  was  marketed,  provided  that  the 
obtained material is not subsequently used 
for other multiplication or propagation. 
Article 13 
1. By way of derogation from  Articles  1  0 
and 11, the sale of propagating material to 
a farmer by the holder of  the patent or with 
his  consent  for ·agricultural  use  implies 
authorisation  for  the  farmer  to  use  the 
product of his harvest for reproduction or 
propagation by him on his own farm,  the 
scope of  and procedure for this derogation 
corresponding to those under Article 14 of 
Regulation (EC) No 2100/94. 
2. By way of derogation from Articles  10 
and  11,  the  sale  of breeding  stock  to  a 
farmer by the holder of the patent or with 
his  consent  implie~ authorisation  tor  the 
farmer  to  use  the  protected  livestock  for 
breeding  purposes  on  his  own  farm,  in 




The protection referred to in Articles 8 and 
9  shall  not  extend  to  biological  material 
obtained .  from  the  multiplication  or 
propagation  of  biological  material 
marketed in the territory of  a Member State 
by  the · holder · of the  patent  or  yvith  his 
consent,  if  . the  · multiplication  or 
propagation  necessarily  resul~s  from . the 
application  for  which  the  biological 
material  was  marketed,  provided  that  the 
obtained material is not subsequently used 
for other multiplication or propagation. 
Article 11 
· 1. By  way  of derogation from  Articles  8 
and 9, the sale of propagating material to a 
farmer by. the holder of the patent or with 
his  consent  for- agricultural  use  implies 
authorisation  for  the  farmer  to  use  the 
product of his harvest for  reproduction or 
propagation by him on his own.  farm,  the 
scope of and procedure for this derogation 
corresponding to  those  under  Article 4  of 
Regulation (EC) No 2100/94. · 
2. By  way  of derogation  from  Articles  8 
and  9, the sale of breeding stock or other · 
reproductive  material  to  a  farmer  by  the 
holder of the  patent  or  with  his  consent 
implies authorisation tor the farmer to  use 
the  protected livestock for  an agricultural 
purpose.  This  includes  the  sale  for  the 
purposes of pi.rrsuing agricultural activities 
but not the sale within the framework or for 




'-,Initial proposal  Amended proposal 
· 3. The  extent  and  the  conditions  of the  3. Unchanged 
derogation  provided  for  in· paragraph · 2 
shall  be  determined  by  national  laws, 
regulations and practices. 
CHAPTER III  .CHAPTER Ill.-
Compulsory cross-licensing  Compulsory cross-Hcem;ing . 
Article 14 
1. Where  a  breeder  cannot  acquire  or  1. Unchanged 
.exploit  a  plant  variety_  right  without 
infringing a prior patent, he may apply for 
a compulsory licence for non-exclusive use 
of the  invention  protected  by  the  patent 
inasmuch as the licence is necessary for the 
exploitation  of  the  plant  variety  to  be 
protected,  subject  to .  payment  of . an 
appropriate  royalty. · Member States  shall 
provide  .  t}J.at  where · ·such  a  licence  is 
granted,  the  holder  of the  patent  will  be 
enti!led  to  a  cross-licence  on  reasonable 
terms to use the protected variety; 
2. Where  the :holder  of  a  patent  on  a  · 2. Unchanged 
biotechnological-invention cannot exploit it 
withouf infringing  a  prior  plant  variety 
right, . he: may_ apply  for  a  compulsory 
licence for  non-exclusive  use  of the  plant 
variety  protected- by  that right;  subject  to 
payment  of  an  · ·appropriate  _ royalty. · 
Member States  shall  provide  that  where 
such a licence is granted, the holder of the 
variety  .  right  will  be.  entitled  to  a 
cross-licence  on  reasonable  terms  to  use 
the protected inv,ention. ·  · 
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\ .' .  - Initial proposal  Amended proposal· 
3. Applicants for the licences referred to in  3. Unchanged 
paragraphs  1  and  2  above  · must 
demonstrate that: 
·(a)  they have applied unsuccessfully to  (a) Unchanged  , 
the  holder of the  patent  or of the 
(b) 
plant  variety  right  to  obtain  a 
contractual licence;. 
exploitation of the plant variety or  (b) 
the invention for which the licence 
is  requested  is  dictated  by  the 
public-interest and the plant variety 
ot  the  invention  constitutes 
significant technical progress. 
the  plant  variety  or  the  invention 
constitutes  significant  technical 
progress of considerable economic 
interest 
4. Each  Member State  shall  designate  the  4. Each  Member State  shall  designate  the 
authority  or  authorities  responsible  for  authority  or .  authorities  responsible  for 
granting the licence.  The licence shall  be  granting the licence. 
granted  principally  for  the  supply  of the 
domestic · market  of  the  Member State 
which has granted the licence. 
CHAPTER IV 




Deposit, access and re.:.deposit of a 
biological material  · 
Article 13 
I. Where an invention involves the  use  of  1.  Unchanged 
or concerns a biological  material which is 
not  available  to  the  public  and  which 
..  cannot be described in a patent application 
in such a manner as to enable the invention 
to be reproduced by a person skilled in the 
art,  the  description  shall  be  considered 
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Initial proposal 
(a)  the  biologiCal  material  has  been 
deposited, 'no later than  the  date 
on- which  the  patent  application 
was  filed,  with  a. recognised 
depositary  institution.  At  least 
the · - international  depositary 
authorities  which  acquired  this 
status  by  virtue  of Article 7  of 
the  Budapest  Treaty  of 
28 April 1977  on.  the 
International  Recognition  of the 
deposit,. of micro-organisms  for 
the purposes of patent procedure, 
hereinafter  referred  to  as  the 
"Budapest  Treaty",  shall  be 
recognised; 
(b)  the  application  as  fil~d .  contains 
such  relevant  information  as  ·is 
available .to  the  applicant on the 
characteristics  of the ·biological 
. material deposited; 
(c)  the  patent  application  states  the 
name  of  the  · depository 
institution  ·and  , the  accession 
··number. 
2. ·  Access  to. the  deposited  biological 
material  shall  be  provided  •. through  the 
supply of  a sample: 
(a)  up to· the  first publication of the 
patent application,  only to  those 
persons who. ate authorised under 
national patent law; 
(b)  between  the  first  publication  of 
the  application' and  the  granting 
of  the  patent,  •  to  .  anyone 
requesting  it or,' if the  applicant 
so  requests,  only  to  an 
independent ·expert; 
(c)  after the patent has been granted, 
and  notwithstanding.  revocation 
or cancellation of  the  patent,  to 
anyone requesting· it.  · 
Amended proposal 
2.' Unchariged 
39 Initial proposal  Amended proposal 
3. The sample shall be supplied only if the  3. Unchanged 
person  requesting  it  undertakes.  for  the 
..  term during which the patent is in force: 
(a)  not· to  make  it  or  any  matter 
derived from it available to third 
parties and 
(b)  not  to  use  it  or  any  matter 
derived  _from  it- except  for 
experimental purposes, 
unless  the  patent  holder  or 
applicant,  as  applicable,  expressly 
waives such an undertaking. 
4. At  the  applicant's · request,  where  an  4. Unchanged 
. application is refused or withdrawn, access 
to the deposited material shall be limited to 
an  independent  expert  for  twenty  years 
from  the  date  on  which  the  patent 
application  was  filed.  In  that  case,. 
paragraph 3 shall apply. 
5. The  applicant's  requests  referred  to  in  5. Unchanged 
point (b) of  paragraph 2 and in paragraph 4 
may only be made up to the date on which 
the  technical ·preparations  for  publishing 
the patent application are deemed to have . 
been completed. 
Article 16  Article 14 
1. If the  biological. material  deposited  in  I. Unchanged 
accordance  with  Article 15  ceases  to  be 
available  from  the _  recognised  depositary 
institutions, a new deposit of the material. 
shall  be  permitted  ori  the  same  terms  as 
those laid down in the Budapest Treaty. 
40 
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2. Any  new deposit shali  be  accompanied  2.  Unchanged 
by  a  statement · signed  by  the  appli~ant 
certifying  that  the  newly  deposited 
biological  mateiial  is  the  same  as  that 
originally deposited. 
CHAPTERV 
· Burden of proof  .  . 
Article 17 
1. If the  subject-matter  of a  patent. is  a 
process for .obtaining a new product, then, 
when .the same product is produced by any 
other party~ it shall, in the absence of  proof 
to  the  contrary, be deemed  to  have  been 
obtained by the patented process.-
2. In the adduction of  proof to the contrary, 
the legitimate interests 'of the defendant in 
protecting his  ~anufacturing and business. 








1. Member States shall bring into force the  1. Member States shall bring into force the 
laws,  .  regulations  and  administrative  laws,  regulations  and  administrative 
provisions  necessary. to  comply  with  this  provisions . necessary  to  comply  with  this 
Directive , not  later- than  1 January 2000.  Directive  not  later · than  1 January 1999. 
They  shall _  immediately  inform  the  They  ·shall  immediately  inform  · the 




. I Initial proposal  Amended proposal 
When  Member States·  adopt  these·  Unchanged, 
measures, these shall contain a reference to . 
this Directive or shall be  accompanied by 
such reference at the time of their official 
publication.  The  procedure ·  for  such 
. reference  shall  .  be  adopted  by 
Member States  .. · 
2. Member States shall communicate to the  2.  Unchanged 
Commission  · the  text  of ·_  the  main 
provisions  of  national  law  which  they 
adopt in the field covered by this Directive. 
Article 16 
Every five  years ·after the transposition of 
this  Directive  the  Commission  shall 
publish  a  report  on .  any  ... Problems 
-encountered with regard to the-relationship 
between  this  Directive  and  international 
agreements  on  the  protection  of human 
rights to  which the  Member States have 
acceded or on which they have cooperated. 
The report shall be forwarded to .European 
Parliament and the Council. 
. Article 19  Article 17 
This Directive shall enter into force on the  Unchanged 
20th day following that of  its publication.in 
· the · Official  Journal  of  the  European  . 
Communities. 
Article 20 
This  Directive  is  addressed  to  the  Unchanged 
Member States. 
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